

Special Issue

Hepatitis B Virus Infection: From Cell Entry to Carcinogenesis. Understanding Viral Replication, Cell Pathogenesis, Disease and Treatments

Message from the Guest Editor

Human hepatitis B virus (HBV) infection can progress to severe chronic diseases and hepatocellular carcinoma, which unfortunately are currently highly prevalent worldwide. While the availability of a prophylactic vaccine has reduced new cases over the decades, a therapeutic solution for chronic hepatitis B is still unavailable. On the other hand, important advances have been achieved on HBV virology. However, a comprehensive knowledge of some fundamental steps and factors involved in virus replication, persistence, and pathogenesis are still unreachable, and therefore, more research is required to accomplish strategies controlling HBV. To contribute new knowledge about this serious human pathogen, this Special Issue will bring together original research papers or review manuscripts on HBV infection with focus on viral replication and persistence, cell pathogenesis, hepatic disease, and anti-viral treatments.

Guest Editor

Dr. Rodrigo A. Villanueva

Centro Ciencia & Vida, Fundación Ciencia & Vida, Avda. Zanartu 1482, Nunoa, Santiago 7780272, Chile

Deadline for manuscript submissions

closed (30 April 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/106375

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).